Acepodia, Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.acepodia.com

Country

Cayman Islands

Exchange

Taipei Exchange

Acepodia is a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care.

It develops AD2C targeting GPC3 for HCC which is in preclinical stage. Its portfolio also includes ACE 1831 targeting CD20 that is in phase 1 clinical trial, and The company is based in Grand Cayman, the Cayman Islands.

Key Stats

52-Week Range

NT$10.85NT$19.15

Beta0.48

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-1.30

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.